Top

Published in:

Open Access 01-08-2014 | Epidemiology

Differences in metastatic patterns in relation to time between primary surgery and first relapse from breast cancer suggest synchronized growth of dormant micrometastases

Authors: Hanna Dillekås, Monica Transeth, Martin Pilskog, Jörg Assmus, Oddbjørn Straume

Published in: Breast Cancer Research and Treatment | Issue 3/2014

Abstract

A significant variation in the metastatic pattern among breast cancer patients exists. Clinical observations suggest that these differences are related to time to recurrence (TTR), thus suggesting a common systemic growth signal at the time of surgery. Our goal was to identify a marker for synchronized growth of micrometastases. To quantify the metastatic pattern at first relapse, 180 patients with metastatic breast cancer were studied. Standard deviation (SD) of lesions size and lesion number was calculated and served as a marker for variation. Patients with low SD (multiple/similar sized lesions) were assumed to have synchronized growth, whereas patients with high SD were assumed to have unsynchronized growth. Patients were grouped according to TTR; early (< 3 years-) or late (> 3 years- after surgery). In patients not receiving systemic adjuvant treatment, median SD was significantly lower in the early group (2.5 mm) compared with 6.4 mm in the late group (p = 0.005). In node negative patients, median SD was significantly lower in the early group (3.0 mm) when compared with the late group (5.7 mm, p = 0.02). An additional drop in SD was observed immediately after end of adjuvant endocrine therapy. Our results identify SD as a marker of synchronized metastatic growth in breast cancer. A metastatic phenotype characterized by multiple similar sized metastases, suggesting synchronized onset of growth of micrometastases was predominantly found in patients recurring early after surgery and was counteracted by adjuvant treatment. Systemic growth signals caused by surgery might be antagonized during the time window following surgery.

Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ (2008) Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100(16):1179–1183. doi:10.1093/jnci/djn233 PubMedCrossRef

Demicheli R, Biganzoli E, Ardoino I, Boracchi P, Coradini D, Greco M, Moliterni A, Zambetti M, Valagussa P, Gukas ID, Bonadonna G (2010) Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrence. Cancer Sci 101(3):826–830. doi:10.1111/j.1349-7006.2009.01472.x PubMedCrossRef

Ribelles N, Perez-Villa L, Jerez JM, Pajares B, Vicioso L, Jimenez B, de Luque V, Franco L, Gallego E, Marquez A, Alvarez M, Sanchez-Munoz A, Perez-Rivas L, Alba E (2013) Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Res 15(5):R98. doi:10.1186/bcr3559 PubMedCentralPubMedCrossRef

Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10):1684–1691. doi:10.1200/JCO.2009.24.9284 PubMedCrossRef

Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, Cuzick J (2013) Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 105(19):1504–1511. doi:10.1093/jnci/djt244 PubMedCentralPubMedCrossRef

Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC (2011) Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat 129(2):607–616. doi:10.1007/s10549-011-1564-5 PubMedCrossRef

Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28(20):3271–3277. doi:10.1200/JCO.2009.25.9820 PubMedCrossRef

Goss P, Allan AL, Rodenhiser DI, Foster PJ, Chambers AF (2008) New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target? APMIS 116(7–8):552–568. doi:10.1111/j.1600-0463.2008.001059.x PubMedCrossRef

Hanin L (2013) Seeing the invisible: how mathematical models uncover tumor dormancy, reconstruct the natural history of cancer, and assess the effects of treatment. Adv Exp Med Biol 734:261–282. doi:10.1007/978-1-4614-1445-2_12 PubMedCrossRef

10.

Holmgren L, O’Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1(2):149–153PubMedCrossRef

11.

Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450(7171):903–907. doi:10.1038/nature06309 PubMedCrossRef

12.

Ranganathan AC, Adam AP, Aguirre-Ghiso JA (2006) Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle 5(16):1799–1807PubMedCentralPubMedCrossRef

13.

Sosa MS, Bragado P, Debnath J, Aguirre-Ghiso JA (2013) Regulation of tumor cell dormancy by tissue microenvironments and autophagy. Adv Exp Med Biol 734:73–89. doi:10.1007/978-1-4614-1445-2_5 PubMedCentralPubMedCrossRef

14.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrutia G, Valentini M, Wang Y, Peto R, Adjuvant Tamoxifen: Longer Against Shorter Collaborative G (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816. doi:10.1016/S0140-6736(12)61963-1 PubMedCentralPubMedCrossRef

15.

Straume O, Shimamura T, Lampa MJ, Carretero J, Oyan AM, Jia D, Borgman CL, Soucheray M, Downing SR, Short SM, Kang SY, Wang S, Chen L, Collett K, Bachmann I, Wong KK, Shapiro GI, Kalland KH, Folkman J, Watnick RS, Akslen LA, Naumov GN (2012) Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci USA 109(22):8699–8704. doi:10.1073/pnas.1017909109 PubMedCentralPubMedCrossRef

16.

Murthy SM, Goldschmidt RA, Rao LN, Ammirati M, Buchmann T, Scanlon EF (1989) The influence of surgical trauma on experimental metastasis. Cancer 64(10):2035–2044PubMedCrossRef

17.

Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, Rafii S (2001) Vascular trauma induces rapid but transient mobilization of VEGFR2(+) AC133(+) endothelial precursor cells. Circ Res 88(2):167–174PubMedCrossRef

18.

Indraccolo S, Stievano L, Minuzzo S, Tosello V, Esposito G, Piovan E, Zamarchi R, Chieco-Bianchi L, Amadori A (2006) Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proc Natl Acad Sci USA 103(11):4216–4221PubMedCentralPubMedCrossRef

19.

Ceelen W, Pattyn P, Mareel M (2014) Surgery, wound healing, and metastasis: recent insights and clinical implications. Crit Rev Oncol Hematol 89(1):16–26. doi:10.1016/j.critrevonc.2013.07.008 PubMedCrossRef

20.

Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G (1996) Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 41(2):177–185PubMedCrossRef

21.

Demicheli R, Valagussa P, Bonadonna G (2001) Does surgery modify growth kinetics of breast cancer micrometastases? Br J Cancer 85(4):490–492. doi:10.1054/bjoc.2001.1969 PubMedCentralPubMedCrossRef

22.

Demicheli R, Ardoino I, Boracchi P, Coradini D, Agresti R, Ferraris C, Gennaro M, Hrushesky WJ, Biganzoli E (2010) Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast. BMC Cancer 10:656. doi:10.1186/1471-2407-10-656 PubMedCentralPubMedCrossRef

23.

Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20(17):3628–3636PubMedCrossRef

24.

Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63(1):181–187PubMedCrossRef

25.

Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14(10):2738–2746PubMed

26.

Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, Investigators AL (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135–1141. doi:10.1016/S1470-2045(10)70257-6 PubMedCrossRef

27.

Willis L, Graham TA, Alarcon T, Alison MR, Tomlinson IP, Page KM (2013) What can be learnt about disease progression in breast cancer dormancy from relapse data? PLoS ONE 8(5):e62320. doi:10.1371/journal.pone.0062320 PubMedCentralPubMedCrossRef

28.

Naumov GN, Folkman J, Straume O, Akslen LA (2008) Tumor-vascular interactions and tumor dormancy. Apmis 116(7–8):569–585PubMedCrossRef

29.

Halsted WS (1907) I. the results of radical operations for the cure of carcinoma of the breast. Ann Surg 46(1):1–19PubMedCentralPubMedCrossRef

30.

Fisher B, Montague E, Redmond C, Barton B, Borland D, Fisher ER, Deutsch M, Schwarz G, Margolese R, Donegan W, Volk H, Konvolinka C, Cohn I Jr, Lesnick G, Cruz AB, Lawrence W, Nealon T, Butcher H, Lawton R (1977) Comparison of radical mastectomy with alternative treatments for primary breast cancer. A first report of results from a prospective randomized clinical trial. Cancer 39(6):2827–2839PubMedCrossRef

31.

Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, Menard C, Lippman ME, Lichter AS, Altemus RM (2003) Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer 98(4):697–702. doi:10.1002/cncr.11580 PubMedCrossRef

32.

Agarwal S, Pappas L, Neumayer L, Kokeny K, Agarwal J (2014) Effect of breast conservation therapy versus mastectomy on disease-specific survival for early-stage breast cancer. JAMA surg. doi:10.1001/jamasurg.2013.3049 PubMed

33.

Fisher B (1999) From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. Eur J Cancer 35(14):1963–1973PubMedCrossRef

34.

Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569–575. doi:10.1001/jama.2011.90 PubMedCrossRef

35.

Walters S, Maringe C, Butler J, Rachet B, Barrett-Lee P, Bergh J, Boyages J, Christiansen P, Lee M, Warnberg F, Allemani C, Engholm G, Fornander T, Gjerstorff ML, Johannesen TB, Lawrence G, McGahan CE, Middleton R, Steward J, Tracey E, Turner D, Richards MA, Coleman MP, Group IMW (2013) Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000–2007: a population-based study. Br J Cancer 108(5):1195–1208. doi:10.1038/bjc.2013.6 PubMedCentralPubMedCrossRef

36.

Uhr JW, Pantel K (2011) Controversies in clinical cancer dormancy. Proc Natl Acad Sci USA 108(30):12396–12400. doi:10.1073/pnas.1106613108 PubMedCentralPubMedCrossRef

37.

Norton L (1988) A gompertzian model of human breast cancer growth. Cancer Res 48(24 Pt 1):7067–7071PubMed

38.

Speer JF, Petrosky VE, Retsky MW, Wardwell RH (1984) A stochastic numerical model of breast cancer growth that simulates clinical data. Cancer Res 44(9):4124–4130PubMed

39.

Withers HR, Lee SP (2006) Modeling growth kinetics and statistical distribution of oligometastases. Semin Radiat Oncol 16(2):111–119PubMedCrossRef

40.

Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7(11):834–846. doi:10.1038/nrc2256 PubMedCentralPubMedCrossRef

41.

Chambers AF, Goss PE (2008) Putative growth characteristics of micrometastatic breast cancer. Breast Cancer Res 10(6):114. doi:10.1186/bcr2197 PubMedCentralPubMedCrossRef

42.

Meltzer A (1990) Dormancy and breast cancer. J Surg Oncol 43(3):181–188PubMedCrossRef

43.

Gao F, Tan SB, Machin D, Wong NS (2007) Confirmation of double-peaked time distribution of mortality among Asian breast cancer patients in a population-based study. Breast Cancer Res 9(2):R21PubMedCentralPubMedCrossRef

44.

Retsky MW, Demicheli R, Hrushesky WJ, Baum M, Gukas ID (2008) Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS 116(7–8):730–741. doi:10.1111/j.1600-0463.2008.00990.x PubMedCrossRef

45.

Gagliato Dde M, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, Hortobagyi GN, Chavez-Macgregor M (2014) Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 32(8):735–744. doi:10.1200/JCO.2013.49.7693 PubMedCrossRef

46.

Torres L, Ribeiro FR, Pandis N, Andersen JA, Heim S, Teixeira MR (2007) Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res Treat 102(2):143–155. doi:10.1007/s10549-006-9317-6 PubMedCrossRef

47.

Cummings MC, Simpson PT, Reid LE, Jayanthan J, Skerman J, Song S, McCart Reed AE, Kutasovic JR, Morey AL, Marquart L, O’Rourke P, Lakhani SR (2013) Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol. doi:10.1002/path.4288

48.

Barista I, Baltali E, Gullu IH, Guler N, Celik I, Saracbasi O, Tekuzman G, Kars A, Ozisik Y, Ruacan S, Atahan IL, Firat D (1996) Factors influencing the distribution of metastases and survival in metastatic breast carcinoma. Am J Clin Oncol 19(6):569–573PubMedCrossRef

49.

Hormbrey E, Han C, Roberts A, McGrouther DA, Harris AL (2003) The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis. Clin Cancer Res 9(12):4332–4339PubMed

50.

O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79(2):315–328PubMedCrossRef

51.

Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O’Reilly MS (2001) Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 61(5):2207–2211PubMed

52.

Petrelli F, Barni S (2012) Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression. Med Oncol 29(5):3282–3290. doi:10.1007/s12032-012-0310-0 PubMedCrossRef

53.

Dominici L, Najita J, Hughes M, Niland J, Marcom P, Wong YN, Carter B, Javid S, Edge S, Burstein H, Golshan M (2011) Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Res Treat 129(2):459–465. doi:10.1007/s10549-011-1648-2 PubMedCentralPubMedCrossRef

54.

Badwe R (2013) Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: a randomized controlled trial. In: SABCS, San Antonio

55.

Fisher B, Gunduz N, Saffer EA (1983) Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43(4):1488–1492PubMed

Title: Differences in metastatic patterns in relation to time between primary surgery and first relapse from breast cancer suggest synchronized growth of dormant micrometastases
Authors: Hanna Dillekås
Monica Transeth
Martin Pilskog
Jörg Assmus
Oddbjørn Straume
Publication date: 01-08-2014
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-014-3057-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Prognosis of synchronous bilateral breast cancer: a review and meta-analysis of observational studies

Long-term cognitive function change among breast cancer survivors

Leptomeningeal disease and breast cancer: the importance of tumor subtype

ERβ splice variant expression in four large cohorts of human breast cancer patient tumors

Association study of susceptibility loci with specific breast cancer subtypes in Chinese women

Cardiac glycosides and the risk of breast cancer in women with chronic heart failure and supraventricular arrhythmia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer